Overview

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Genexine, Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab